Dermal and melanocortin research
PT-141
Lyophilized dermal or melanocortin research peptide
PT-141 / bremelanotide is a melanocortin receptor research peptide studied around central melanocortin signaling.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesFor laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, mitigate, or prevent disease.
Keep sealed, cold, dry, and protected from heat swings. Confirm product-specific storage on arrival.
Packed for transit stability with order support available for warm-weather routes.
Batch-linked certificate support is available through the documentation desk.
Araştırma bağlamı
PT-141 araştırma profili
PT-141, also known as bremelanotide in pharmaceutical literature, is a cyclic melanocortin receptor agonist studied primarily for central melanocortin signaling. Research examines receptor pharmacology, neural pathway activation, behavioral endpoints, pharmacokinetics, and differences from pigment-focused alpha-MSH analogs. It is related to Melanotan II by molecular lineage but is generally selected when the study centers on central signaling rather than melanogenesis. Human pharmaceutical studies provide a developed evidence context for regulated bremelanotide products, but those data do not establish the identity, approval, safety, or performance of a research-use catalog batch. Product selection should remain based on the molecular reference, format, and documentation.
Molecular class
Cyclic melanocortin heptapeptide
Sequence / composition
A cyclic seven-residue peptide from the Melanotan II lineage, with non-native residue substitutions.
Research design note
The cyclic design supports central melanocortin receptor pharmacology studies and should not be treated as a vascular peptide.
Önerilen mekanizma
A cyclic melanocortin receptor agonist developed from the Melanotan II lineage. Proposed effects are primarily central and involve MC3R/MC4R-related neural circuits rather than a direct vascular mechanism.
Çalışmalarda bildirilen etkiler
- Animal studies report activation of central melanocortin pathways and sexual-response behaviors.
- Controlled human studies of regulated bremelanotide reported changes in sexual-desire or distress endpoints in selected populations.
- Nausea, flushing, headache, transient blood-pressure increases, and hyperpigmentation are important reported effects.
Yaygın araştırma sonlanım noktaları
Melanocortin receptor potency, neural activation, behavioral response, validated desire and distress scores, blood pressure, heart rate, nausea, pigmentation, and pharmacokinetics.
Kanıtlar ve sınırlamalar
Preclinical and controlled human evidence exists for regulated bremelanotide. Research material is not represented as equivalent to an approved drug product.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
Where can I find product documentation?
Contact support with the product name and any relevant order or batch reference to request available documents.
How can I compare pack options?
Where multiple pack sizes are available, Azure shows the price per listed vial so you can compare catalog value directly.